Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

被引：0
作者：
Michael T. Nurmohamed
Ben A. C. Dijkmans
机构：
[1] VU University Medical Centre,Department of Rheumatology
[2] Jan van Breemen Institute,undefined
[3] Slotervaart Hospital,undefined
来源：
Drugs | 2005年 / 65卷
关键词：
Rheumatoid Arthritis; Methotrexate; Infliximab; Etanercept; Adalimumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Over the last decade, several new drugs have become available for the treatment of patients with rheumatoid arthritis. These agents include the new disease-modifying antirheumatic drug (DMARD) leflunomide and the biologic agents, tumor necrosis factor (TNF)-α antagonists and an interleukin (IL)-1 receptor antagonist.
引用
收藏
页码：661 / 694
页数：33
相关论文
共 454 条
[1]  
Yelin E(2002)Guidelines for the management of rheumatoid arthritis: 2002 update Arthritis Rheum 46 328-46
[2]  
Wanke LA(1999)An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline Arthritis Rheum 42 1209-18
[3]  
Cooper NJ(2000)Economic burden of rheumatoid arthritis: a systematic review Rheumatology (Oxford) 39 28-33
[4]  
Fries JF(1996)Guidelines for the management of rheumatoid arthritis Arthritis Rheum 39 713-22
[5]  
Aletahaq D(2000)Current treatment paradigms in rheumatoid arthritis Rheumatology 39 30-5
[6]  
Stamm T(2003)Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study Ann Rheum Dis 62 944-51
[7]  
Kapral T(2001)Rheumatoid arthritis: treatment of early disease Rheum Dis Clin North Am 27 405-14
[8]  
Boers M(2002)Cardiovascular risk profile of antirheumatic agents in patients with osteoar-thritis and rheumatoid arthritis Drugs 62 1599-609
[9]  
Nurmohamed MT(2001)Systemic low-dose glucocorticoid in rheumatoid arthritis Rheum Dis Clin North Am 27 389-403
[10]  
van Halm V(2003)Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001–2002 Curr Opin Rheumatol 15 127-31
12345678910